Dog_lover
04-14-2008, 10:21 AM
Dutton Associates updates its coverage of MediciNova (Nasdaq:MNOV) maintaining a Strong Speculative Buy rating and a $10.00 price target. The 11-page report by Dutton senior analyst Wayne T. Lottinville, CFA is available at To view links or images in this forum your post count must be 1 or greater. You currently have 0 posts. as well as from First Call, Bloomberg, Zacks, Reuters, Knobias, and other leading financial portals.
More... (To view links or images in this forum your post count must be 1 or greater. You currently have 0 posts.*To view links or images in this forum your post count must be 1 or greater. You currently have 0 posts.)
More... (To view links or images in this forum your post count must be 1 or greater. You currently have 0 posts.*To view links or images in this forum your post count must be 1 or greater. You currently have 0 posts.)